Scynexis

For the quarter ended 30 June 2026, SCYNEXIS reported earnings of $0.63 per share, after -$1.12 in the prior year. Revenue fell 83.09 percent to $0.2 million (prior year: $1.4 million). » Más en finanzen.net

Scynexis approved a 1-for-8 reverse stock split at an extraordinary general meeting, to take effect on May 29, 2026, and to be traded from June 1, 2026 under the existing ticker symbol but with a new CUSIP. The measure aims to regain compliance with the Nasdaq Capital Market minimum bid price requirement. Outstanding shares will fall from about 79.5 million to around 9.9 million; authorized shares will be reduced proportionally and option exercise prices adjusted accordingly. Shareholders will receive a cash payment for fractional shares, and holdings held at custodians will be adjusted automatically. » Más en de.investing.com

SCYNEXIS has entered into a purchase agreement with institutional and accredited investors for a private placement with gross proceeds of about $40 million at an offering price of $0.92 per unit. The transaction includes 34,750,000 common shares as well as pre-funded warrants and accompanying warrants that, if fully exercised for cash, could raise an additional $52.2 million (exercise price $1.20). The company expects to close around April 1, 2026, names Guggenheim Securities as placement agent and plans to use net proceeds for working capital and general corporate purposes, with cash expected to be sufficient through mid-2029. CEO Dr. David Angulo also purchased shares and warrants; a shareholder meeting to increase authorized shares is planned within 90 days. » Más en de.investing.com